Sunday, February 15, 2026 2/15/2026

Winship National Clinical Trials Network Lead Academic Participating Site

Award Number: UG1CA233247
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: COOPERATIVE AGREEMENT
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 01/02/2025
PERIOD OF PERFORMANCE END DATE: 02/28/2026

Group Awards By:

View Award Description

Winship National Clinical Trials Network Lead Academic Participating Site - Project Summary/Abstract Winship Cancer Institute of Emory University (Winship) is the only NCI-designated Comprehensive Cancer Center in the state of Georgia, despite Georgia being the eighth most populous state in the nation. Within Georgia, cancer is the second leading cause of death, with 48,850 new cancer cases diagnosed each year. Since March 1, 2014, when Winship became a NCI National Clinical Trials Network (NCTN) Lead Academic Participating Site (LAPS), Winship has played a unique role in leading research in the NCTN groups in the four most important measures of success: 1) Winship has exceeded its enrollment target for NCTN trials; 2) Winship has provided significant leadership to both the NRG and the ECOG-ACRIN groups; 3) Winship has been active in designing and supporting clinical trials in all NCTN network groups; and 4) Winship leadership has been successful in mentoring the next generation of cancer researchers. Winship members are well represented in the NCI’s NCTN steering committees and task forces. Approximately 30% of Winship patients enrolled to NCTN trials are of African descent. Additionally, Winship has been among the top three centers for the past four years and the highest in 2016 to enroll children and adolescents with cancer to the Children’s Oncology Group (COG) indicating Winship’s leadership in the NCTN. The Atlanta VA Medical Center, currently an affiliate of our LAPS, was the top enroller to NCTN trials nationally among VA hospitals for the first two years of the award period. Winship has also leveraged its statewide partnerships with the Georgia National Community Oncology Research Program (NCORP) and the Georgia minority underserved NCORP to enhance accruals to NCTN trials throughout Georgia. With an enthusiastic institutional commitment to its role in the NCTN, Winship proposes the following specific aims for this application: 1) Expand its many leadership roles within the NCTN and the network groups; 2) Enroll Winship patients onto a wide spectrum of NCTN trials, emphasizing enrollment of historically under-represented minority patients; 3) Provide mentorship and guidance to early career investigators for participation in the NCTN; and 4) Develop novel clinical trials in the NCTN based on research ideas generated at Winship.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $682,746 )
2025	2025	EMORY UNIVERSITY	201 DOWMAN DR NE	ATLANTA	GA	30322	DEKALB	USA	Cancer Treatment Research	000	6	3/3/2025	SUPPLEMENT FOR EXPANSION	$431,208
2025	2025	EMORY UNIVERSITY	201 DOWMAN DR NE	ATLANTA	GA	30322	DEKALB	USA	Cancer Treatment Research	001	6	7/29/2025	SUPPLEMENT FOR EXPANSION	$251,538
														Subtotal = $682,746

Issue Date FY: 2024 ( Subtotal = $762,746 )
2024	2024	EMORY UNIVERSITY	201 DOWMAN DR NE	ATLANTA	GA	30322	DEKALB	USA	Cancer Treatment Research	004	6	9/9/2024	NON-COMPETING CONTINUATION	$80,000
2024	2024	EMORY UNIVERSITY	201 DOWMAN DR	ATLANTA	GA	30322	DEKALB	USA	Cancer Treatment Research	001	6	2/21/2024	NON-COMPETING CONTINUATION	$646,811
2024	2024	EMORY UNIVERSITY	201 DOWMAN DR NE	ATLANTA	GA	30322	DEKALB	USA	Cancer Treatment Research	003	6	7/12/2024	NON-COMPETING CONTINUATION	$0
2024	2024	EMORY UNIVERSITY	201 DOWMAN DR NE	ATLANTA	GA	30322	DEKALB	USA	Cancer Treatment Research	002	6	4/22/2024	NON-COMPETING CONTINUATION	$35,935
2024	2023	EMORY UNIVERSITY	201 DOWMAN DR	ATLANTA	GA	30322	DEKALB	USA	Cancer Treatment Research	000	5	12/11/2023	NON-COMPETING CONTINUATION	$0
														Subtotal = $762,746

Issue Date FY: 2023 ( Subtotal = $718,680 )
2023	2023	EMORY UNIVERSITY	201 DOWMAN DR	ATLANTA	GA	30322	DEKALB	USA	Cancer Treatment Research	000	5	2/23/2023	NON-COMPETING CONTINUATION	$718,680
														Subtotal = $718,680

Issue Date FY: 2022 ( Subtotal = $718,680 )
2022	2022	EMORY UNIVERSITY	201 DOWMAN DR	ATLANTA	GA	30322	DEKALB	USA	Cancer Treatment Research	001	4	3/2/2022	NON-COMPETING CONTINUATION	$718,680
2022	2021	EMORY UNIVERSITY	201 DOWMAN DR	ATLANTA	GA	30322	DEKALB	USA	Cancer Treatment Research	000	3	10/28/2021	NON-COMPETING CONTINUATION	$0
														Subtotal = $718,680

Issue Date FY: 2021 ( Subtotal = $743,680 )
2021	2021	EMORY UNIVERSITY	201 DOWMAN DR	ATLANTA	GA	30322	DEKALB	USA	Cancer Treatment Research	000	3	3/2/2021	NON-COMPETING CONTINUATION	$743,680
														Subtotal = $743,680

Issue Date FY: 2020 ( Subtotal = $718,680 )
2020	2020	EMORY UNIVERSITY	1599 CLIFTON RD.	ATLANTA	GA	30322	DEKALB	USA	Cancer Treatment Research	002	2	2/27/2020	NON-COMPETING CONTINUATION	$0
2020	2020	EMORY UNIVERSITY	1599 CLIFTON RD.	ATLANTA	GA	30322	DEKALB	USA	Cancer Treatment Research	001	2	2/24/2020	NON-COMPETING CONTINUATION	$718,680
2020	2019	EMORY UNIVERSITY	1599 CLIFTON RD.	ATLANTA	GA	30322	DEKALB	USA	Cancer Treatment Research	000	1	2/3/2020	NEW	$0
														Subtotal = $718,680

Issue Date FY: 2019 ( Subtotal = $718,680 )
2019	2019	EMORY UNIVERSITY	1599 CLIFTON RD.	ATLANTA	GA	30322	DEKALB	USA	Cancer Treatment Research	000	1	3/5/2019	NEW	$718,680
														Subtotal = $718,680

Grand Total All Awards = $5,063,892

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Winship National Clinical Trials Network Lead Academic Participating Site

Award Number: UG1CA233247

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: COOPERATIVE AGREEMENT

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 01/02/2025

PERIOD OF PERFORMANCE END DATE: 02/28/2026

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer